Delivery Order SPE2DB22D3016-SPE2DB25FBDZ3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Nucynta ER 50 mg tablets (60-count), with a contract ceiling value of $1,398.37. This is a firm fixed-price delivery order with no set-aside designation, demonstrating competitive award to the contractor. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 23, 2025. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $4,416.12 to AmerisourceBergen Drug Corp for the supply of Nucynta ER 100 mg tablets (60-count units) on August 5, 2025, with completion targeted for August 6, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed from the vendor's Conshohocken, Pennsylvania location, which serves as the company's corporate headquarters and primary distribution...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Nucynta ER 150 mg tablets (60-count units) with a ceiling value of $3,263.99. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract is set to complete by August 5, 2025, and performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $1,899.74 to AmerisourceBergen Drug Corp for the supply of Nucynta ER 150 mg tablets (60-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The order represents a child contract action under...
- The Defense Logistics Agency awarded a delivery order valued at $1,592.44 to AmerisourceBergen Drug Corp for Nucynta ER 50 mg tablets (60-count supply) on July 25, 2025, with an ultimate completion date of July 28, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $1,367.15 to AmerisourceBergen Drug Corp for the supply of Nucynta ER 150 mg tablets (60-count) on August 5, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at the awardee's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. The order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Nucynta ER 100 mg tablets (60-count units) valued at $2,944.08 under a firm fixed-price contract. This delivery order represents a child contract issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling and extends through December 2026. The award was competitively...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Nucynta 50 mg tablets (100 count) with a ceiling value of $1,225.04. This firm fixed-price delivery order, with an ultimate completion date of July 23, 2025, represents a direct fulfillment of pharmaceutical needs through the federal medical supply chain. The contract is not set-aside and was competitively awarded, reflecting AmerisourceBergen's established capability as a...
- The Defense Logistics Agency awarded a delivery order valued at $2,244.18 to AmerisourceBergen Drug Corp for the supply of Nucynta ER 250 mg tablets (60-count) on July 31, 2025, with completion targeted for August 1, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The award carries no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Nucynta ER 150 mg tablets (60-count units) with a ceiling value of $1,110.11. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBDZ3Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Nucynta ER 200 mg tablets (60-count units) valued at $4,050.39. This firm fixed-price contract, with an ultimate completion date of August 6, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement needs. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to military healthcare systems worldwide. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen has demonstrated consistent capability in fulfilling DLA procurement requirements through competitive awards covering diverse therapeutic domains and product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.1k | 8/5/25 |